Table 4.

LVEDV and LVESV derived from echocardiography analysis

	CON (n = 25)	Group A (n = 27)	Group B (n = 26)	Group C (n = 26)
	(95 % CI)	(95 % CI)	(95 % CI)	(95 % CI)
LVEDV by echocardiography, ml
Baseline	157.7 ± 26.1	153.1 ± 27.9	151.7 ± 21.8	154.5 ± 26.7
	(148.0 to 167.3)	(141.8 to 165.4)	(142.9 to 160.5)	(143.7 to 165.3)
6 months	156.9 ± 27.2	151.2 ± 26.3	149.8 ± 23. 5	152.8 ± 24.7
	(144.8 to 168.9)	(139.3 to 162.0)	(138.6 to 158.1)	(142.1 to 163.5)
Change from baseline	−2.5 ± 14.5	−4.0 ± 11.3	−3.7 ± 12.5	−3.8 ± 15.4
	(−8.9 to 3.9)	(−10.5 to 1.8)	(−9.3 to 2.7)	(−10.4 to 2.9)
12 months	157.5 ± 27.6	149.4 ± 25.8†	148.5 ± 20.7†	150.2 ± 26.0
	(145.3 to 169.7)	(137.2 to 160.5)	(137.9 to 156.2)	(138.4 to 162.1)
Change from baseline	−3.9 ± 18.7	−7.9 ± 13.9	−6.6 ± 10.6	−7.6 ± 18.0
	(−12.2 to 4.4)	(−14.3 to −0.8)	(−11.5 to −1.4)	(−15.8 to 0.6)
LVESV by echocardiography, ml
Baseline	93.9 ± 17.3	90.8 ± 19.3	90.5 ± 18.3	97.0 ± 25.1
	(88.9 to 100.9)	(83.0 to 98.6)	(83.2 to 97.9)	(86.8 to 107.1)
6 months	90.6 ± 21.4	77.2 ± 19.0*†‡	83.2 ± 14.7	92.2 ± 21.6
	(80.8 to 100.3)	(69.3 to 85.0)	(76.3 to 90.0)	(82.9 to 101.6)
Change from baseline	−4.0 ± 10.8	−13.4 ± 10.0†‡	−10.5 ± 11.9	−5.3 ± 12.0
	(−8.9 to 0.8)	(−17.6 to −9.3)	(−16.0 to −4.9)	(−10.5 to −0.2)
12 months	89.8 ± 22.3*	71.1 ± 19.8*†‡	73.4 ± 17.1*†‡	89.1 ± 22.6*
	(80.8 to 100.3)	(62.6 to 79.7)	(64.5 to 82.2)	(78.8 to 99.4)
Change from baseline	−6.4 ± 15.9	−20.5 ± 13.3†‡	−19.6 ± 11.1†‡	−9.4 ± 16.3
	(−13.3 to 0.4)	(−26.2 to −14.7)	(−25.3 to −13.9)	(−16.8 to −1.9)

^* p < 0.05, vs baseline; ^† p < 0.05, vs control; ^‡ p < 0.05, vs group C. CON control group; group A bone marrow mononuclear cell (BMC) infusion within 1 day after percutaneous coronary intervention (PCI); group B BMC infusion at 3–7 days after PCI; group C BMC infusion at 7–30 days after PCI; LVEDV left ventricular end-diastolic volume; LVESV left ventricular end-systolic volume